Study ID: Amgen FOURIER 20110118
Title:

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease

Description:

The purpose of this study is to find out more about an investigational product called AMG 145. AMG 145 is a fully human antibody that binds to a natural protein called PCSK9 that is produced by the liver. By binding to PCSK9, AMG 145 allows the LDL receptor (a protein present in the liver) to move the LDL-cholesterol more efficiently out of the bloodstream. This study is designed to see whether treatment of dyslipidemia with AMG 145 in people who have experienced a prior myocardial infarction or stroke, and who are taking a highly effective dose of a statin, reduces the risk of recurring or additional cardiovascular events. Participants in this study have clinically evident cardiovascular disease.

Location:
Fargo Region
Principal Investigator:
David Clardy, MD
Disease:
Heart
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list